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Angiotensin-converting enzyme (ACE), an enzyme
that plays a major role in vasoactive peptide metabo-
lism, is a type 1 ectoprotein, which is released from the
plasma membrane by a proteolytic cleavage occurring
in the stalk sequence adjacent to the membrane anchor.
In this study, we have discovered the molecular mecha-
nism underlying the marked increase of plasma ACE
levels observed in three unrelated individuals. We have
identified a Pro1199 3 Leu mutation in the juxtamem-
brane stalk region. In vitro analysis revealed that
the shedding of [Leu1199]ACE was enhanced compared
with wild-type ACE. The solubilization process of
[Leu1199]ACE was stimulated by phorbol esters and in-
hibited by compound 3, an inhibitor of ACE-secret-
ase. The results of Western blot analysis were consist-
ent with a cleavage at the major described site
(Arg12032Ser1204). Two-dimensional structural analysis
of ACE showed that the mutated residue was critical for
the positioning of a specific loop containing the cleav-
age site. We therefore propose that a local conforma-
tional modification caused by the Pro1199 3 Leu muta-
tion leads to more accessibility at the stalk region for
ACE secretase and is responsible for the enhancement of
the cleavage-secretion process. Our results show that
different molecular mechanisms are responsible for the
common genetic variation of plasma ACE and for its
more rare familial elevation.
Angiotensin I-converting enzyme (DCP1, EC 3.4.15.1, ACE)1
is a zinc metallopeptidase that plays an important role in blood
pressure regulation by cleaving the inactive decapeptide angio-
tensin I to angiotensin II, a potent vasopressor octapeptide. It
also inactivates bradykinin, a potent vasodilator peptide (1).
There are two ACE isoforms transcribed from a single ACE
gene by two alternate promoters (2). Somatic ACE (170 kDa) is
synthesized by vascular endothelial cells as well as several
types of epithelial cells, whereas testis ACE (110 kDa) is ex-
pressed exclusively by male germinal cells (3, 4).
Somatic ACE consists of two homologous catalytic domains,
a juxtamembrane stalk region, a hydrophobic transmembrane
domain of 17 amino acids, and a 30-residue C-terminal cytoso-
lic domain (5). Thus ACE is primarily an integral membrane
protein anchored to the plasma membrane by its C-terminal
segment. But the membrane-bound enzyme can be fully solu-
bilized in vitro by detergents or limited proteolytic cleavage (6).
In vivo, a soluble form of the enzyme exists in plasma and other
body fluids (7). Plasma ACE is known to be strongly modulated
by a common polymorphism in linkage disequilibrium with an
insertion/deletion polymorphism (8). Although this quantita-
tive trait locus (QTL) was localized on the ACE gene itself (9),
the functional variant has not yet been identified.
Human plasma ACE is derived from endothelial cells by
post-translational cleavage. Several membrane-anchored pro-
teins are solubilized by limited proteolysis with release of their
extracellular domains. This common phenomenon, also re-
ferred to as “shedding” displays typical characteristics such as
induction by phorbol esters, calcium ionophores, and unidenti-
fied serum factor; inhibition of the shedding protease by hy-
droxamate-based metalloprotease inhibitors; localization of the
shedding event at the cell surface; and structural requirements
of the juxtamembrane stalk that determine cleavage efficiency
(10–12). Cleavage secretion of ACE is topologically constrained
to an accessible stalk region of at least 11 residues in length
and requires a minimum distance of 3 residues from the prox-
imal extracellular domain and 8 residues from the membrane
(10). Furthermore, mutational analysis of the stalk region has
shown that conservation of the amino acid sequence was not
essential for shedding, even though the secretase seems to have
a weak preference for cleavage after Arg or Lys residues (10,
13, 14). Thus, the critical parameter, for cleavage efficiency
seems to be the conformation of the stalk more than the amino
acid sequence. In addition, experiments using the homologous
stalk region of CD4 (which is not cleaved) to construct a chi-
meric ACE revealed that the distal extracellular domain of
ACE also has a prominent role for determining the cleavage
(14).
Here we report the identification of a Pro1199 3 Leu muta-
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tion found associated with high plasma ACE levels in three
unrelated Dutch individuals. In vitro study of this mutation
was performed, and effects of this mutation on the solubiliza-
tion process of ACE were investigated. We present experimen-
tal results showing that this single amino acid change in the
stalk region is responsible for an enhancement of the cleavage
and secretion of ACE in an ACE-secretase activity-dependent
manner. A hypothesis implicating a modification of the ACE
structure caused by the point mutation that leads to better
accessibility for the ACE secretase is proposed.
EXPERIMENTAL PROCEDURES
Subjects and Biological Findings—Three unrelated individuals
(HOL.2, HOL.10, and HOL.19) were identified through a screening of
plasma ACE levels in a population of patients referred to the hospital
for various causes. The study included the measurement of several
clinical, paraclinical, and biological parameters. Plasma ACE enzy-
matic activity was measured by a commercial kit (ACEcolor, Fujizoki
Pharmaceutical Co. Ltd., Tokyo, Japan) using Gly-His-Leu as sub-
strate. The complete clinical report has been described in Kramers et
al.2
Reagents—Phorbol 12-myristate 13-acetate (PMA), MCDB-131 me-
dium, Dulbecco’s modified Eagle’s medium, CHAPS, and hydrocortisone
were from Sigma. Fetal calf serum was from Valbiotech (Paris, France).
Phosphate-buffered saline, L-glutamine, penicillin-streptomycin, and
geneticin were from Life Technologies, Inc. Human recombinant
epidermal growth factor (hEGF) and EXGEN 500 were from Eurome-
dex (Souffelweyersheim, France). Compound 3 [N-[-D,L-[2-(hydroxy-
aminocarbonyl)methyl]-4-methylpentanoyl]-L-3-(tert-butyl-alanyl-L-
alanine, 2- aminoethyl amide) was provided by Dr. Roy A. Black, Im-
munex Research and Development Corp. (Seattle, WA).
PCR Amplification and Sequencing—Genomic DNA of all subjects
was used as template for PCR amplification. Specific primers were
designed to amplify each of the 26 exons of the ACE gene, according to
our own sequence determination and to the published data (Gen-
BankTM/EBI accession numbers AC002345 and AF118569). The primer
sequences are available upon request. Exon 25 amplification was per-
formed with oligonucleotides 59-CATGTTGAGCTACTTCAAGC-39
(sense) and 59-CCAGTGTTCCCATCCCAG-39 (antisense), using the fol-
lowing cycling parameters: one denaturation step at 95 °C, 4 min; 31
cycles (95 °C, 30 s; 60 °C, 30 s; 72 °C, 30 s); and one final elongation step
at 72 °C, 10 min. Purified PCR products were submitted to direct
sequencing using fluorescent dideoxyterminator (ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction Kit, PE Biosystems) on
an ABI 377 sequencer.
Site-directed Mutagenesis—A single Pro (CCG) to Leu (CTG) muta-
tion at position 1199 was introduced into pACE-WT (or peACE), an
expression vector containing the full-length somatic ACE cDNA con-
trolled by the SV40 early promoter (15). An oligonucleotide-directed
mutagenesis system (QuickChange site-directed mutagenesis kit,
Stratagene) was used according to the manufacturer’s recommendation.
The following oligonucleotides containing the desired mutation were
used: 59-GCAGTACAACTGGACGCTGAACTCCGCTCGC-39 (sense); 59-
GCGAGCGGAGTTCAGCGTCCAGTTGTACTGC-39 (antisense). Mu-
tant cDNAs were screened by DNA sequencing. One mutant containing
the desired mutation was selected and designed as pACE(Leu1199). The
entire cDNA fragment of this construct was sequenced to ensure that no
other mutations occurred. The same protocol was used to introduce the
Pro1199 3 Leu mutation into plasmid pACE-CF containing the coding
sequence for the signal peptide, the C-terminal domain, and the trans-
membrane domain of human endothelial ACE (16). The mutant con-
taining the desired mutation was designed as pACE-CF(Leu1199).
Transient Expression of pACE-WT, pACE(Leu1199), pACE-CF, and
pACE-CF(Leu1199)—pACE-WT, pACE(Leu1199), pACE-CF, and pACE-
CF(Leu1199) were expressed in COS-7 cells. Transient transfections
were performed by using polyethyleneimine suspension in a commer-
cially available solution (EXGEN 500). COS-7 cells (250 3 103/well)
were plated on a 6-well plate and incubated 24 h in Dulbecco’s modified
Eagle’s medium supplemented by 10% heat-inactivated fetal calf se-
rum, 2 mM L-glutamine, 100 units/ml penicillin-streptomycin and then
treated with a mix containing 2 mg of plasmid, 4 ml of EXGEN 500, and
NaCl (150 mM) in a final volume of 100 ml. The same protocol was used
to express pACE-WT and pACE(Leu1199) in HMEC-1 (human microder-
mal endothelial cells transfected and immortalized with a pBR-322-
based plasmid containing the coding region for the SV40 A gene prod-
uct, large T antigen, Ref. 17) except that they were grown in MCDB-131
medium supplemented by 20% heat-nactivated fetal calf serum, 2 mM
L-glutamine, 100 units/ml penicillin-streptomycin, 10 ng/ml hEGF, 1
mg/ml hydrocortisone, and 6 ml of EXGEN 500 were used for transfec-
tion. Cells were incubated overnight with the transfection mix.
Expression of pACE(Leu1199) in CHO Cells—pACE(Leu1199) was in-
troduced by cotransfection with neomycin resistance plasmid pSV2neo
into CHO cells. CHO cells (1 3 106) were plated on a 10-cm2 Petri dish,
incubated 24 h, then treated with a mix containing 2.95 mg of pACE-
(Leu1199), 500 ng of pSV2neo, 6 ml of EXGEN 500, and NaCl (150 mM)
in a final volume of 100 ml. The transfected cells were grown in Dul-
becco’s modified Eagle’s medium supplemented with 10% heat-inacti-
vated fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin-strep-
tomycin, and 750 mg/ml geneticin. Single colonies of primary G418-
resistant transformants were assayed for the expression of pACE
(Leu1199) by Western blot analysis and enzymatic assays (see below).
Cell lines expressing pACE(Leu1199) were selected and purified by sub-
cloning using limiting dilution. Establishment of a CHO cell line ex-
pressing pACE-WT has been previously described (15).
Metabolic Labeling and Immunoprecipitation—Wild-type and mu-
tant ACE CHO cell lines with similar cellular contents of ACE activity
were seeded in 60-mm dishes at a density of 2 3 106 cells/dish and
grown to confluency. Metabolic labeling and immunoprecipitation were
performed as previously described (18), except that immunoprecipita-
tion was performed using antiserum HKE obtained from sheep immu-
nized against pure human kidney ACE and protein G-Sepharose (Sig-
ma). Proteins were resolved by 7.5% SDS-polyacrylamide gel
electrophoresis and revealed by autoradiography.
Preparation of Subcellular Fractions—CHO cells expressing wild-
type ACE and ACE(Leu1199) were scraped and suspended in buffer A
containing 50 mM HEPES pH 7.5, 0.25 M sucrose, and 5 mM MgCl2. All
steps were performed at 4 °C. The cell suspension was homogenized
using a glass-Teflon homogenizer for 30 s and then centrifuged at
1,000 3 g for 10 min. The pellet was resuspended in buffer A and
centrifuged at 10,000 3 g for 10 min. The pellet was solubilized in
CHAPS (8 mM) and conserved as a lysosomal fraction. The supernatant
was centrifuged again at 105,000 3 g for 1 h. The sedimented mem-
branes were washed with buffer A and solubilized in CHAPS (8 mM),
and the supernatant was conserved as a cytosolic fraction.
Enzymatic Characterization—Cells were scraped and washed with
phosphate-buffered saline and then centrifuged at 1,200 3 g for 10 min.
The pellet was dissolved in CHAPS (8 mM). After stirring for 12 h to
solubilize the membrane-bound ACE, the suspension was centrifuged
at 12,000 3 g for 10 min, and the supernatant was used for enzymatic
assays.
Secreted ACE was obtained from the culture medium of transfected
cells grown in serum free medium.
All enzymatic studies were performed using p-benzoyl-L-glycyl-L-
histidyl-L-leucine (Hip-His-Leu, Bachem, Switzerland) as substrate.
The detection and quantification of hippuric acid released from the
Hip-His-Leu were performed by HPLC as previously described (15).
Kinetic parameters for the hydrolysis of Hip-His-Leu were determined
from Michaelis-Menten plots using ENZFITTER software. All enzy-
matic studies were performed under initial rate conditions.
Western Blot Analysis—Two different rabbit antisera were used to
characterize expressed forms of ACE: antisera 3 and 4 (18) which were
raised against synthetic peptides corresponding to sequences of the
C-terminal ACE (see Fig. 1). Membrane-bound and secreted ACE were
collected as described above and analyzed by SDS-PAGE on a 7.5%
polyacrylamide gel, transferred to a nitrocellulose membrane (Pall
Gelman Sciences) in a buffer containing 25 mM Tris-HCl, pH 8.3, and
150 mM glycine using a semi-dry transfer system (Bio-Rad). Western
blotting was performed in TBST buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 0.05% Tween 20) with antiserum 3 (1:500 dilution) or anti-
serum 4 (1:500 dilution). The peroxidase-conjugated anti-rabbit IgG
(Jackson Immunoresearch) (1:5000 dilution) was used as secondary
antibody. The detection step was carried out with ECL Western blotting
detection reagents (Amersham Pharmacia Biotech) as recommended by
the manufacturer.
Computer-assisted Structural Analysis—Multiple alignment of do-
main 1 (N-terminal domain) and domain 2 (C-terminal domain) of
several ACE orthologs was performed using ClustalW program (19).
The sequence data used are available in the Swiss-Pro database under
accession numbers P12821, P09470, and Q10751.
2 C. Kramers, S. M. Danilov, J. Deinum, I. V. Balyasnikova, N.
Scharenberg, M. Looman, F. Boomsma, M. H. De Keijzer, C. Van Duijn,
S. Martin, F. Soubrier, and G. J. Adema, submitted manuscript.
Molecular Basis for Increased Plasma ACE Levels5526
 at Erasm
us M
C M
edical Library on N
ovem
ber 9, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Hydrophobic cluster analysis (HCA), a two-dimensional structure
prediction method based on the detection and comparison of the struc-
tural segments constituting the hydrophobic core of globular protein
has been described elsewhere (20, 21). ACE sequences were submitted
to HCA analysis, and domain 1 and domain 2 of ACE orthologs were
aligned according to hydrophobic clusters determined by HCA plots.
Optimal alignment was performed using combined data from ClustalW
and HCA analysis.
RESULTS
Biochemical Parameters—Three unrelated subjects with marked in-
creases in plasma ACE levels were identified through a screening of
patients referred to a general hospital (55.8, 83.8, and 86.6 units/liter).
Using the colorimetric assay ACEcolor, normal values of plasma ACE
fluctuate between 8.3 and 21.4 units/liter. Plasma ACE levels are 2.5–
4-fold higher than highest levels found in the normal population. All
other biological and paraclinical parameters measured were normal.
Sequencing of the ACE Gene Exons—A heterozygote point mutation
was identified in exon 25 of the ACE gene. This point mutation is a C-T
transition, introducing a leucine in position 1199 instead of a proline
found normally at this position (Fig. 1). No other mutation was present
in ACE gene exons from these subjects. Cotransmission of high plasma
ACE levels and the Pro11993 Leu mutation was observed in the family,
although this mutation was not found in a large sample of Dutch
subjects (Kramers et al.).2
To elucidate the mechanism by which this mutation was responsible
for the high plasma ACE levels observed in these individuals, an in
vitro study using site-directed mutagenesis was undertaken.
Expression of Wild-type ACE and [Leu1199]ACE in COS-7 and
HMEC-1 Cells—The expression plasmid pACE-WT (or peACE) was
used to direct the synthesis of wild-type ACE (16). The expression
plasmid pACE(Leu1199) is identical to pACE-WT except for a single Pro
(CCG) to Leu (CTG) mutation at position 1199 of the coding sequence of
somatic ACE and was used to direct the synthesis of [Leu1199]ACE.
The kinetic parameters for Hip-His-Leu hydrolysis of the wild-type
ACE and of the [Leu1199]ACE, calculated from a Michaelis-Menten plot,
were not significantly different (Fig. 2). The Km and the Vmax values of
the [Leu1199]ACE were similar to that of the wild-type ACE (3.33 6 0.11
mM versus 2.51 6 0.12 mM and 0.35 6 0.007 nmol/ml/min21 versus
0.34 6 0.008 nmol/ml/min21).
Both plasmids were transiently expressed in COS-7 cells for compar-
ing the ability of cells to secrete [Leu1199]ACE with that of the wild-type
ACE (Fig. 3, A, C, and E). Transfected cells were grown in serum-free
medium for indicated times before the ACE enzymatic activity was
measured with a Hip-His-Leu substrate by HPLC. No significant dif-
ference was observed in levels of cell-associated ACE between the
wild-type form and [Leu1199]ACE during the time-course study (Fig.
3A). In contrast, levels of soluble [Leu1199]ACE activity were higher
than wild-type ACE suggesting that the rate of release was enhanced
(Fig. 3C). The percentage of solubilization, which was defined as the
ratio of the enzymatic activity in the medium to the total enzymatic
activity (medium 1 cells) was in average 1.5-fold higher for
[Leu1199]ACE, as compared with wild-type ACE in COS-7 cells with a
maximum difference of 2.5-fold at 24 h (Fig. 3E).
We also investigated the rate of secretion of [Leu1199]ACE in
HMEC-1, an endothelial cell line, which does not express ACE, because
endothelium is a major site of expression of ACE in vivo and the source
for plasma ACE (Fig. 3; B, D, and F). Higher levels of soluble
[Leu1199]ACE activity were observed, as compared with wild-type ACE,
and lower cell associated ACE activity was observed. The rate of solu-
bilization was in average 2.5-fold higher for [Leu1199]ACE compared
with the wild-type form.
These data showed that a leucine in position 1199 instead of a proline
in ACE protein leads to an enhancement of cleavage and secretion of
ACE. Thus, both in an endothelial cell type and a nonendothelial cell
type, differences between wild-type ACE and [Leu1199]ACE release
observed in vitro are consistent with the plasma ACE increase observed
in subjects bearing this mutation.
Biosynthesis and Secretion of Metabolically Labeled Wild-type ACE
and [Leu1199]ACE—CHO cells stably transfected with the expression
plasmid pACE-WT or pACE(Leu1199) were used to investigate the role
of the Pro11993 Leu mutation on ACE secretion. Cells were labeled for
30 min with [35S]methionine/cysteine and chased in serum-free medium
for the indicated periods of time (Fig. 4). Affinity precipitates of cell
lysates of transfected cells revealed two bands of immunoreactive ACE
around 170 kDa. The lower band, which disappeared after 24 h of chase,
corresponds to the underglycosylated form of ACE, and the upper band,
which appeared at 1 h of chase, corresponds to the glycosylated form of
ACE. The secreted [Leu1199]ACE appeared earlier than soluble wild-
type ACE at 4 h of chase (Fig. 4B), whereas only traces of soluble
wild-type ACE were visible after 8 h of chase (Fig. 4A). Furthermore,
soluble [Leu1199]ACE increased rapidly in contrast with wild-type ACE,
which was difficult to detect in the medium even after 16 h of chase.
The metabolic labeling results were consistent with the kinetic ex-
periments based on ACE activity, indicating that [Leu1199]ACE was
released more efficiently from the cell surface than wild-type ACE.
Subcellular Localization of [Leu1199]ACE—To test whether the
Pro11993 Leu mutation influences the intracellular trafficking of ACE,
distribution of ACE was determined in various compartments of CHO
cells stably transfected with either wild-type ACE or [Leu1199]ACE
grown for 3 or 24 h in serum-free medium. Medium was then collected,
and lysosomal, cytosolic, and membranous compartments were sepa-
rated by successive centrifugations. ACE activity was measured in each
fraction and expressed as percentage of total ACE activity (Fig. 5). We
determined that total ACE activity was equivalent for wild-type ACE
and [Leu1199]ACE.
ACE activity measured in the cytosol for wild-type ACE and
[Leu1199]ACE was very low, indicating that these proteins are rapidly
addressed to the membrane. A higher proportion of total ACE (38.6 6
8.5% for wild-type ACE and 24.9 6 9.7% for [Leu1199]ACE at 3 h) was
detected in lysosomal fraction. At 3 h (Fig. 5A) only 6% of total
[Leu1199]ACE was detected in membranous compartment, whereas high
levels of [Leu1199]ACE (34% of total ACE) was observed in the medium.
At the same time, wild-type ACE levels were similar in membranous
compartment and medium (17 and 16% of total ACE respectively). This
difference between [Leu1199]ACE and wild-type ACE was more pro-
nounced at 24 h (Fig. 5B).
Immunological Characterization of Membrane-bound and Soluble
[Leu1199]ACE—To map the cleavage site of [Leu1199]ACE, Western blot
analyses using specific antibodies were performed (Fig. 6). Antiserum 3
was raised against sequences from the C-terminal side of the
Arg12032Ser1204 cleavage site (22) and antiserum 4 was directed
against a synthetic peptide located at the N-terminal side of this cleav-
age site (Fig. 1).
CHO cells stably transfected with either wild-type ACE and
[Leu1199]ACE were grown to subconfluence and then incubated in se-
rum-free medium for 48 h. Medium and CHAPS-solubilized cell lysates
were analyzed on SDS-PAGE gel followed by Western blotting. Anti-
serum 3 failed to recognize wild-type or [Leu1199]ACE secreted in the
medium, indicating that cleavage occurred before amino acid 1214. In
contrast antiserum 4 was able to recognize the soluble form of wild-type
and [Leu1199]ACE, indicating that cleavage occurred after amino acid
FIG. 1. C-terminal sequence of wild-type ACE from Gly1135 to
Glu1230. The proline mutated into leucine in the three individuals is
underlined. The cleavage site previously described is shown by an
arrow. Sequences of synthetic peptides used for the production of anti-
sera 4 and 3 are indicated.
FIG. 2. Lineweaver-Burk plots for hydrolysis of Hip-His-Leu
by wild-type ACE and [Leu1199]ACE. Wild-type ACE (M) was com-
pared with [Leu1199]ACE (E). Assay was performed in a mix containing
100 mM potassium phosphate, pH 8.3, 300 mM NaCl, and 10 mM ZnSO4
at 37 °C.
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1162. Both antisera recognized wild-type and [Leu1199]membrane-
bound ACE.
Effects of PMA and Compound 3 on [Leu1199]ACE Secretion—To
document the involvement of the already characterized ACE secretase
in increased shedding of [Leu1199]ACE, we investigated the effects of
compound 3 on the [Leu1199]ACE solubilization process. Transfected
cells were grown in a serum-free medium containing (or not) compound
3 (50 mM), and the time course of secretion was investigated over a 48 h
period (Fig. 7A). After 3 h, 31% of [Leu1199]ACE was secreted from the
untreated cells, whereas in compound 3-treated cells, only 4% of
[Leu1199]ACE was secreted at the same time. This effect was still
observed after 48 h of treatment. So compound 3 inhibited
[Leu1199]ACE to the same extent that it inhibited wild-type ACE
secretion.
COS-7 cells were transfected with wild-type ACE and [Leu1199]ACE
and were thereafter grown in serum-free medium containing (or not)
PMA (500 nM). The time course of secretion was investigated over a 3-h
period (Fig. 7B). PMA enhanced the rate of [Leu1199]ACE cleavage
secretion considerably. For example, after 3 h, 55% of [Leu1199]ACE was
secreted from the PMA-treated cells, whereas, in untreated cells, only
FIG. 3. Time course of wild-type and
[Leu1199]ACE secretion. Enzymatic
activity of wild-type ACE (M) and
[Leu1199]ACE (E) transiently expressed in
COS-7 cells (A, C, E) or in HMEC-1 (B, D,
F) was measured for 48 h in serum-free
medium. Medium samples (C, D) and de-
tergent lysates (A, B) were collected at
indicated time points and assayed with
ACE substrate Hip-His-Leu. E and F are
representations of the time course of ACE
secretion, respectively, in COS-7 and
HMEC-1 cells. The results are mean 6
S.E. of duplicate determinations of two
independent experiments. Where error
bars are not evident, S.E. is less than the
figure resolution.
FIG. 4. Pulse-chase analysis of the wild-type ACE and [Leu1199]ACE. CHO cells expressing wild-type ACE (A) or [Leu
1199]ACE (B) were
pulse-labeled with [35S]methionine/cysteine for 30 min and then chased with serum-free medium from 0 to 16 h. An aliquot of cell lysates (200 ml)
and medium (1 ml) were immunoprecipitated with HKE antiserum (3 ml).
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20% of [Leu1199]ACE was secreted at the same time. We observed a
significant difference in solubilization of PMA-treated cells compared
with untreated cells as early as 15 min after treatment. No similar
effect was observed with wild-type ACE secretion.
Role of the N-terminal Domain: Expression of [Leu1199]ACE-CF in
COS-7 Cells and Effect of PMA on Secretion—The possible effect of the
N-terminal domain on [Leu1199]ACE solubilization was investigated
using expression plasmid pACE-CF containing full-length somatic ACE
cDNA except the coding sequence for the N-terminal domain (16).
pACE-CF and pACE-CF(Leu1199) were transiently expressed in COS-7
cells (Fig. 8A). At 6 h, nearly 50% of ACE-CF was solubilized in medium
whereas at the same time only 20% of wild-type somatic ACE was
secreted (compare Figs. 3E and 8A), confirming the lower solubilization
of the two domain-containing enzyme. We observed a significantly
higher rate of release for [Leu1199]ACE-CF as compared with ACE-CF
after 1 h (31 versus 7%, respectively). The percentage of solubilization
was in average 1.8-fold higher for [Leu1199]ACE-CF as compared with
ACE-CF in COS-7 cells.
We also investigated the effect of PMA on ACE-CF and
[Leu1199]ACE-CF solubilization. (Fig. 8B). PMA enhanced the rate of
solubilization of ACE-CF and [Leu1199]ACE-CF. After 15 min, 14% of
ACE-CF and 62% of [Leu1199]ACE-CF were secreted from PMA-treated
cells, whereas in untreated cells only 5% of ACE-CF and 20% of
[Leu1199]ACE-CF were solubilized at the same time. A PMA effect was
more pronounced on [Leu1199]ACE-CF solubilization in the early times
of a kinetic analysis, but the difference was less evident between
ACE-CF and [Leu1199]ACE-CF after 2 h.
Structural Analysis—The HCA plots of domain 1 (N-terminal do-
main) and domain 2 (C-terminal domain) of several ACE orthologs were
compared to produce an optimal alignment. Fig. 9 shows this alignment
for the region of interest, i.e. close to proline 1199. HCA plots revealed
that the shape of the hydrophobic cluster immediately upstream of this
proline is typical of a b-strand, which would presumably end at that
particular proline. An insertion of seven residues (NSARSEG in human
ACE) is readily detectable before the next downstream pattern of hy-
drophobic residues. This insertion contains the cleavage site after
Arg1203 of domain 2 except in the case of chicken domain 2 whose amino
acid sequence differs at that site (Fig. 9). No hydrophobic residue was
found within this insertion, thus suggesting that it corresponds to a
loop. Interestingly, proline 1199 is located at the N-terminal side of this
putative loop. Following the insertion, the shape of the hydrophobic
cluster, although it presents an ambivalent character, might indicate
the presence of an a-helix in domain 2 compatible with the constraint of
linking the first extracellular domain to the membrane anchor.
FIG. 5. Subcellular localization of wild-type and [Leu1199]ACE.
Enzymatic activity of wild-type ACE (open bar) or [Leu1199]ACE (filled
bar) was measured in subcellular compartments of CHO cells. The
results are mean 6 S.E. of three independent experiments. A, subcel-
lular localization of wild-type and [Leu1199]ACE in CHO cells grown 3 h
in serum-free medium. B, subcellular localization of wild-type and
[Leu1199]ACE in CHO cells grown 24 h in serum-free medium.
FIG. 6. Western blot analysis of wild-type and [Leu1199]ACE.
Wild-type ACE (WT) or [Leu1199]ACE (MUT) expressed in CHO cells
were analyzed on SDS-PAGE gel. Medium (M) and cell lysates (L) were
collected immediately (To) or 48 h (T48) after a switch to serum-free
medium. Western blot analysis was performed using antisera 3 and 4.
FIG. 7. Effects of PMA and compound 3 on wild-type and
[Leu1199]ACE solubilization. COS-7 cells transiently expressing
wild-type ACE (squares) or [Leu1199]ACE (circles) were grown in a
serum-free medium with (black symbols) or without (white symbols)
pharmacological reagents for indicated times. The solubilization was
estimated by the ratio of enzymatic activity in the medium over total
enzymatic activity (medium 1 cells). Results, expressed in percentage,
are mean 6 S.E. of duplicate determinations of two independent exper-
iments. A, effect of compound 3 (50 mM) on ACE solubilization. Time
course was performed from 3 to 48 h. B, effect of PMA (500 nM) on ACE
solubilization. Time course was performed from 15 to 180 min.
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DISCUSSION
We report a mutation of the ACE gene, which was found in
three apparently healthy unrelated individuals from the same
ethnic origin and selected for having very high plasma ACE
levels. Pathological causes of high plasma levels could be elim-
inated in these individuals. Moreover, the genetic origin of the
very high plasma ACE levels was supported by the Mendelian
transmission of the trait in the families of these subjects
(Kramers et al.).2 Familial elevations of plasma ACE levels
were already described in Japan and Italy, but the molecular
basis has not been elucidated (23, 24).
In view of its large effect, the genetic increase of plasma ACE
levels, which was observed in these subjects could not be at-
tributed to the common polymorphism of the ACE gene, which
explains 30% of plasma ACE variance in the Caucasian popu-
lation and which is in linkage disequilibrium with an insertion/
deletion polymorphism located within intron 16 of the ACE
gene (8, 25).
The complete sequencing of the exons of the ACE gene was
performed to detect a mutation specific to the three individuals.
DNA sequencing revealed a mutation in exon 25 leading to a
Pro1199 3 Leu mutation of the somatic form of ACE. This
mutation was not found in a large series of Caucasian subjects,
and no other mutation was found in the coding sequence of the
three selected subjects.
Because the Pro11993 Leu mutation was located in the stalk
region, which links the transmembrane domain to the first
FIG. 8. Time course of ACE-CF and ACE-CF(Leu1199) secretion
and effect of PMA. A, rate of solubilization of ACE-CF (M) and
ACE-CF(Leu1199) (E) transiently expressed in COS-7 cells. Medium
samples and detergent lysates were collected at indicated time points
and assayed with ACE substrate Hip-His-Leu. The results are mean 6
S.E. of duplicate determinations of two independent experiments. B,
effect of PMA (500 nM) on ACE-CF and ACE-CF(Leu1199) solubilization.
COS-7 cells transiently expressing ACE-CF (squares) or ACE-
CF(Leu1199) (circles) were grown in a serum-free medium with (black
symbols) or without (white symbols) pharmacological reagents for indi-
cated times. Results, expressed in percentage, are mean 6 S.E. of
duplicate determinations of two independent experiments.
FIG. 9. HCA plots of the N-terminal (D1) and C-terminal (D2)
domains of somatic ACE. This figure is limited to the C-terminal
ends of both domains, i.e. when considering the human sequence be-
tween 1135 and 1227 for D2 and 537 and 622 for D1. On these plots, the
sequence, which is duplicated to keep neighbors at the boundaries of the
plot, is written following the parallel and nearly vertical lines. Four
residues are represented by symbols as indicated at the bottom of the
figure. Hydrophobic clusters are drawn when two hydrophobic residues
(FILMVWY) are neighbors in this picture, and a cluster is broken by the
presence of one proline inside it. It has been statistically demonstrated
(31) that these clusters fit with secondary structure elements. Gray
shaded areas correspond to conserved parts of the clusters among
sequences. The last cluster before Pro1199 is clearly a b-strand element.
The cluster following this proline does not have a conserved shape that
allows elucidation of the nature of the corresponding secondary struc-
ture. The last two secondary structures before Pro1199 are indicated by
solid bar and zigzag symbols below the figure.
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extracellular domain, near the identified cleavage site (22), it
was considered as a good candidate, and its functional effect
was further investigated. We introduced the Pro1199 3 Leu
mutation into a somatic ACE expression vector, and we ob-
served, as expected, no difference in enzymatic properties be-
tween the [Leu1199]ACE and the wild-type ACE. The cleavage
secretion process was therefore the most likely to be affected by
the mutation. We investigated the release rate in two different
cell lines, the COS-7 cells already used in previous studies, and
the HMEC-1, an endothelial dermal microvessel cell line,
which does not synthesize ACE. In both cell lines, an increased
secretion rate of [Leu1199]ACE was observed, as compared with
wild-type ACE. The effect was however more pronounced in
endothelial cells with a 2.5-fold increased secretion observed in
average during the time-course study. Metabolic labeling ex-
periments confirmed that [Leu1199]ACE is secreted more effi-
ciently than wild-type ACE. Subcellular localization of
[Leu1199]ACE in CHO cells revealed that this effect is associ-
ated with a slight but selective decrease of membranous ACE
together with an increase in ACE concentration of the medium,
indicating that a global increase of ACE production cannot
explain the phenomenon observed. It is remarkable that an
important part of total ACE is retrieved in the lysosomal frac-
tion, indicating that a high proportion of both mutated and
wild-type ACE is degraded before it is addressed to the mem-
brane or that it is recycled from the membrane.
Two antibodies, raised against peptides flanking the cleav-
age site determined for both human testicular and somatic
ACE (26), were used to determine whether [Leu1199]ACE was
cleaved at the same location as the wild-type enzyme. Indeed,
[Leu1199]ACE is cleaved between amino acid 1162 and 1214, a
result consistent with the cleavage site determined for the in
vitro expressed wild-type somatic and testicular enzymes, and
for the seminal plasma ACE (26). Thus, our results do not favor
the hypothesis of another cleavage site created by the mutation
but suggest a more active cleavage rate at the major site.
However we cannot exclude that a small fraction of secreted
ACE, not detected with antiserum 4, is cleaved at a secondary
cleavage site, such as the one described between Arg1137 and
Leu1138 for human plasma ACE (13).
The cleavage secretion of ACE is an enzymatic process which
can be modulated by pharmacological agents. A hydroxamic
acid-based inhibitor of metalloproteases, compound 3, was
shown to block very effectively the cleavage-processing activity
of testicular ACE in a mouse epithelial cell line (ACE 89) stably
transfected with the rabbit testicular ACE (27). Our data show
that compound 3 completely abolished [Leu1199]ACE secretion
as well as wild-type ACE over a prolonged period of time (12 h),
after which a progressive degradation of the inhibitor likely
enabled secretion to rise again. This clearly indicates that the
increased cleavage-secretion process observed for [Leu1199]
ACE results from the similar enzymatic process to the wild-
type and not from cleavage because of another type of enzyme
or from a nonspecific leakage from the membrane.
Phorbol esters, which activate protein kinase C, were shown
to enhance the rate of ACE cleavage-secretion, with a marked
difference between the somatic and testicular isoforms, the
latter being more strongly solubilized than the first, even after
a short period of incubation (26). The phorbol ester PMA mark-
edly and rapidly increased [Leu1199]ACE solubilization (4–5-
fold), in contrast to wild-type ACE whose secretion was not
significantly increased by PMA.
The cleavage secretion of somatic ACE is lower compared
with testicular ACE, and it has been proposed that the N-
terminal domain could have an inhibitory effect on its secre-
tion. Because both the basal and phorbol ester-induced cleav-
age secretion of [Leu1199]ACE resembled what is observed for
the testicular isoform of ACE, we investigated the hypothesis
that the mutation could suppress an effect of the N-terminal
domain on solubilization. This was achieved by introducing the
mutation in an ACE expression vector lacking the N-domain of
ACE (pACE-CF) (16). At the basal level, secretion of
[Leu1199]ACE-CF was increased 4-fold as compared with the
wild-type ACE-CF in COS-7 cells. After treatment with PMA,
an early 4-fold increase of [Leu1199]ACE-CF secretion rate was
observed as compared with the wild-type ACE-CF. Two kinds
of arguments drawn from our results indicate that the muta-
tion is not acting through the suppression of an inhibitory
effect of the N-terminal domain on the secretion rate. First,
cleavage-secretion of somatic [Leu1199]ACE is lower compared
with C-terminal domain [Leu1199]ACE. Second, the effect of the
Pro1199 3 Leu mutation on secretion increase is also observed
with the recombinant ACE molecule lacking the N-terminal
domain.
It was recently shown that, in the ACE89 cell line, testicular
ACE can make a complex with protein kinase C subunits, and
this complex dissociates in the presence of phorbol ester (28). A
subsequent enhanced effect of ACE secretase was proposed to
explain the phorbol ester-induced cleavage-secretion. In the
cases of both somatic and C-terminal domain ACE (ACE-CF)
with the Pro11993 Leu mutation, the preservation of a higher
solubilization rate under PMA indicates that the increase in
speed of shedding induced by the putative PMA-induced com-
plex dissociation can still be enhanced by a change in
conformation.
Because no data are available on the ACE three-dimensional
structure, we performed multiple alignment deduced from
HCA plots of the N-terminal and the C-terminal domains of
several ACE orthologs to predict secondary structures around
proline 1199. It is remarkable that proline 1199 is highly con-
served among ACE family sequences. Furthermore, this amino
acid is the last common residue of the two domains preceding a
loop specific for the C-terminal domain and which contains the
cleavage site. The insertion of a fairly long loop between two
secondary structures might be an indication of a better acces-
sibility for proline 1199 by the C-terminal domain compared
with the homologous proline 601 in the N-terminal domain.
Proline is known to induce conformational constraints by cre-
ating twists and turns in peptidic sequences. We proposed that
the presence of a leucine in position 1199 instead of a proline
confers more flexibility in this region leading to better accessi-
bility and action of ACE secretase.
Thus, even though it was shown that the cleavage-secretion
process is not constrained by a specific amino acid sequence but
is much more dependent on topological parameters (10), we
show here that an amino acid sequence important for the
conformational state of the juxtamembrane stalk region is crit-
ical for ACE release. More investigation in the structural con-
formation of the stalk region would provide interesting data for
the study of the regulated shedding of ACE and other shedded
membrane-associated proteins.
The elucidation of the molecular basis of a QTL affecting the
plasma concentration of ACE has implications that go beyond
the ACE gene itself. First, it illustrates that a QTL is not
necessarily acting by modifying the expression level of the gene
affected by the QTL, but conformational changes can modify its
secretion rate and, hence, its concentration in a particular
biological fluid where it can be measured in clinical practice.
Second, it shows that the plasma concentration is a biological
phenotype, which can be of limited value, because it does not
necessarily reflect the level of expression at the cellular level.
In the case described here, the membranous concentration of
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ACE is even slightly decreased, and the high plasma concen-
tration is not associated with any detectable pathological effect.
In contrast, it has been shown that the above mentioned com-
mon polymorphism of ACE also affects the cellular level of the
enzyme, where it can cause potential deleterious effects (29,
30). Finally, because the mutation described here cannot ex-
plain interindividual variations of plasma ACE associated with
an insertion/deletion polymorphism of the ACE gene, our re-
sults clearly demonstrate that different molecular mechanisms
account for strong genetic influences on plasma ACE.
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